PharmaBlock Sciences Nanjing Inc Class A (300725) - Net Assets
Based on the latest financial reports, PharmaBlock Sciences Nanjing Inc Class A (300725) has net assets worth CN¥5.50 Billion CNY (≈ $804.64 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.39 Billion ≈ $935.03 Million USD) and total liabilities (CN¥891.08 Million ≈ $130.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300725 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.50 Billion |
| % of Total Assets | 86.05% |
| Annual Growth Rate | 45.47% |
| 5-Year Change | 139.76% |
| 10-Year Change | 2378.91% |
| Growth Volatility | 47.2 |
PharmaBlock Sciences Nanjing Inc Class A - Net Assets Trend (2013–2025)
This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see PharmaBlock Sciences Nanjing Inc Class A stock valuation.
Annual Net Assets for PharmaBlock Sciences Nanjing Inc Class A (2013–2025)
The table below shows the annual net assets of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2025. Also explore 300725 shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.30 Billion ≈ $921.91 Million |
+110.88% |
| 2024-12-31 | CN¥2.99 Billion ≈ $437.17 Million |
+5.48% |
| 2023-12-31 | CN¥2.83 Billion ≈ $414.45 Million |
+6.57% |
| 2022-12-31 | CN¥2.66 Billion ≈ $388.90 Million |
+1.14% |
| 2021-12-31 | CN¥2.63 Billion ≈ $384.52 Million |
+38.69% |
| 2020-12-31 | CN¥1.89 Billion ≈ $277.26 Million |
+155.74% |
| 2019-12-31 | CN¥740.87 Million ≈ $108.41 Million |
+23.53% |
| 2018-12-31 | CN¥599.73 Million ≈ $87.76 Million |
+19.09% |
| 2017-12-31 | CN¥503.59 Million ≈ $73.69 Million |
+98.15% |
| 2016-12-31 | CN¥254.15 Million ≈ $37.19 Million |
+73.41% |
| 2015-12-31 | CN¥146.56 Million ≈ $21.45 Million |
+68.11% |
| 2014-12-31 | CN¥87.18 Million ≈ $12.76 Million |
+24.27% |
| 2013-12-31 | CN¥70.16 Million ≈ $10.27 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PharmaBlock Sciences Nanjing Inc Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9062.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.71 Billion | 27.20% |
| Other Components | CN¥4.59 Billion | 72.80% |
| Total Equity | CN¥6.30 Billion | 100.00% |
PharmaBlock Sciences Nanjing Inc Class A Competitors by Market Cap
The table below lists competitors of PharmaBlock Sciences Nanjing Inc Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kemper Corporation
NYSE:KMPR
|
$1.58 Billion |
|
HeBei Jinniu Chemical Industry Co Ltd
SHG:600722
|
$1.58 Billion |
|
Natco Pharma Limited
NSE:NATCOPHARM
|
$1.58 Billion |
|
Sihui Fuji Electronics Technology Co Ltd
SHE:300852
|
$1.59 Billion |
|
Southern Publishing&Media Co
SHG:601900
|
$1.58 Billion |
|
Hansol Chemica
KO:014680
|
$1.58 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
$1.58 Billion |
|
Kinnevik Investment AB ser. B
ST:KINV-B
|
$1.58 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmaBlock Sciences Nanjing Inc Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,987,552,996 to 6,300,140,082, a change of 3,312,587,086 (110.9%).
- Net income of 183,735,514 contributed positively to equity growth.
- Dividend payments of 65,746,095 reduced retained earnings.
- Other comprehensive income decreased equity by 394,487,309.
- Other factors increased equity by 3,589,084,976.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥183.74 Million | +2.92% |
| Dividends Paid | CN¥65.75 Million | -1.04% |
| Other Comprehensive Income | CN¥-394.49 Million | -6.26% |
| Other Changes | CN¥3.59 Billion | +56.97% |
| Total Change | CN¥- | 110.88% |
Book Value vs Market Value Analysis
This analysis compares PharmaBlock Sciences Nanjing Inc Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.72x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 72.68x to 1.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.64 | CN¥46.31 | x |
| 2014-12-31 | CN¥0.79 | CN¥46.31 | x |
| 2015-12-31 | CN¥1.33 | CN¥46.31 | x |
| 2016-12-31 | CN¥1.85 | CN¥46.31 | x |
| 2017-12-31 | CN¥3.45 | CN¥46.31 | x |
| 2018-12-31 | CN¥3.22 | CN¥46.31 | x |
| 2019-12-31 | CN¥3.97 | CN¥46.31 | x |
| 2020-12-31 | CN¥10.08 | CN¥46.31 | x |
| 2021-12-31 | CN¥12.17 | CN¥46.31 | x |
| 2022-12-31 | CN¥13.28 | CN¥46.31 | x |
| 2023-12-31 | CN¥14.06 | CN¥46.31 | x |
| 2024-12-31 | CN¥14.97 | CN¥46.31 | x |
| 2025-12-31 | CN¥26.95 | CN¥46.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmaBlock Sciences Nanjing Inc Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.31%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.17x
- Recent ROE (2.92%) is below the historical average (15.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 26.07% | 31.17% | 0.69x | 1.22x | CN¥11.25 Million |
| 2014 | 25.82% | 29.32% | 0.75x | 1.17x | CN¥13.77 Million |
| 2015 | 13.68% | 14.64% | 0.79x | 1.18x | CN¥5.36 Million |
| 2016 | 14.72% | 19.17% | 0.63x | 1.22x | CN¥11.59 Million |
| 2017 | 13.56% | 24.59% | 0.48x | 1.15x | CN¥17.65 Million |
| 2018 | 22.24% | 27.89% | 0.63x | 1.27x | CN¥73.39 Million |
| 2019 | 20.53% | 22.96% | 0.64x | 1.39x | CN¥77.98 Million |
| 2020 | 9.72% | 18.02% | 0.42x | 1.28x | CN¥-5.26 Million |
| 2021 | 20.04% | 40.49% | 0.34x | 1.44x | CN¥243.82 Million |
| 2022 | 11.82% | 19.70% | 0.33x | 1.83x | CN¥48.46 Million |
| 2023 | 6.97% | 11.44% | 0.34x | 1.80x | CN¥-85.87 Million |
| 2024 | 7.35% | 13.00% | 0.34x | 1.65x | CN¥-79.22 Million |
| 2025 | 2.92% | 9.31% | 0.27x | 1.17x | CN¥-446.28 Million |
Industry Comparison
This section compares PharmaBlock Sciences Nanjing Inc Class A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,071,852,849
- Average return on equity (ROE) among peers: 7.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmaBlock Sciences Nanjing Inc Class A (300725) | CN¥5.50 Billion | 26.07% | 0.16x | $1.58 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.14 Billion | 22.15% | 4.96x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.29 Billion | 4.72% | 1.33x | $408.67 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $7.08 Billion | 22.94% | 0.22x | $4.29 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $1.54 Billion | 9.43% | 0.69x | $1.75 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $13.42 Billion |
| Hainan Haiyao Co Ltd (000566) | $2.20 Billion | -4.84% | 2.35x | $871.39 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $267.57 Million | 2.03% | 1.53x | $313.28 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $935.36 Million | -7.40% | 1.32x | $975.12 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $11.10 Billion | 9.54% | 0.09x | $3.03 Billion |
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the di… Read more